Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.50 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 2/20 | 0.49 |
| ▸ | TTK | P33981 | 2/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 4/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.45 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028698 | 0.86 | CDK4 (0.51) | CCNA2CDK2ALKJAK3PTK2 | |
| SCHEMBL11029902 | 0.80 | CSF1R (0.44) | JAK3CDK4CCND1 | |
| SCHEMBL11029725 | 0.80 | CCNA2 (0.58) | CCNA2CDK2PLK1CCNA1PLK3 | |
| SCHEMBL11027507 | 0.77 | ALK (0.52) | ALK | |
| SCHEMBL11026445 | 0.76 | EGFR (0.51) | CCNA2CDK2PLK1CCNA1PLK3 | |
| SCHEMBL11033146 | 0.76 | ALK (0.58) | CCNA2CDK2PLK1CCNA1PLK3 | |
| SCHEMBL11033999 | 0.76 | SLC2A1 (0.51) | CCNA2CDK2PIM1TTKPIM2 | |
| SCHEMBL11027989 | 0.76 | CCNT1 (0.53) | CCNA2CDK2PLK1CCNA1PLK3 | |
| SCHEMBL11029699 | 0.75 | ALK (0.57) | ALK | |
| SCHEMBL11026741 | 0.72 | FYN (0.55) | CCNA2CDK2CCNT1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | claimed |
| EP-2665711-A1 | PICOLINAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | claimed |
| WO-2012100135-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | claimed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | claimed |
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2665711-A1 | PICOLINAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2012100135-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ALK, PKN2, ERBB2 | CCNA2 403/4885CDK2 18/4885PLK1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.